Myovant Sciences Ltd.
(NYSE : MYOV)

( )
MYOV After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
-1.67%292.231.4%$590.52m
AMGNAmgen, Inc.
0.07%234.011.3%$503.19m
GILDGilead Sciences, Inc.
1.04%67.781.0%$366.31m
REGNRegeneron Pharmaceuticals, Inc.
1.59%373.532.6%$302.52m
VRTXVertex Pharmaceuticals, Inc.
-0.12%220.001.9%$273.01m
ILMNIllumina, Inc.
-1.95%320.573.5%$231.88m
ARWRArrowhead Pharmaceuticals, Inc.
-3.73%68.2211.4%$207.81m
CLVSClovis Oncology, Inc.
-3.14%11.7214.7%$207.81m
ALXNAlexion Pharmaceuticals, Inc.
-1.53%109.502.0%$195.03m
EXASEXACT Sciences Corp.
-0.15%85.1724.0%$163.33m
AAgilent Technologies, Inc.
0.60%83.431.6%$159.09m
GBTGlobal Blood Therapeutics, Inc.
3.29%78.456.0%$142.09m
BLUEbluebird bio, Inc.
1.49%86.9714.2%$139.80m
BOLDAudentes Therapeutics, Inc.
-0.12%59.441.4%$134.26m
SGENSeattle Genetics, Inc.
-2.32%111.346.1%$128.54m

Company Profile

Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.